Emily Hopewell | Director of Cell and Gene Therapy Manufacturing
Indiana University School of Medicine

Emily Hopewell, Director of Cell and Gene Therapy Manufacturing, Indiana University School of Medicine

Emily Hopewell began her career at the Moffitt Cancer Center as a technologist in the Cell Therapy Facility in 2003. She received her PhD in Cancer Biology from the University of South Florida and returned to the Cell Therapy Facility as a Development Specialist and then Assistant Technical Director. She joined Indiana University in 2018 and is the Director of Cell and Gene Therapy Manufacturing (CGTM) and an Assistant Professor in Clinical Medical and Molecular Genetics. The CGTM group comprises the Vector Production Facility, Cell Immunotherapy and Transduction Facility, and the Bioprocess Development Laboratory. Dr. Hopewell oversees development efforts through clinical production of cell and gene therapies for use in clinical trials and provides leadership, strategic direction and input on education, research and clinical missions within the Cell and Gene Therapy GMP Facilities.

Appearances:



Day 3: Friday 21st May 2021 - Commercialisation, Pricing & Access @ 14:30

Strategies, tech transfer & supply chain: challenges and scale up of product for patient delivery at cryogenic temperatures

last published: 10/May/21 08:45 GMT

back to speakers